The genes <i>AHR</i>, <i>FAS</i>, and <i>FGF2</i> emerged as key markers, forming a robust diagnostic model (NaiveBayes) with an AUC of 0.9.<h4>Conclusion</h4><i>AHR</i>, <i>FAS</i>, and <i>FGF2</i> were identified as potential biomarkers for PAH, influencing cell proliferation and inflammatory responses, thereby offering new insights for PAH prevention and treatment. The gene discussed is FGF2; the disease is pulmonary arterial hypertension.